
Korro Bio, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Korro Bio is a biopharmaceutical company developing RNA-editing therapeutics that use the body's own ADAR enzymes to correct disease-causing mutations, with programs targeting conditions such as alpha-1 antitrypsin deficiency-associated liver disease.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| FORMELA JEAN FRANCOISInsider | Sell | $330K | 23,584at $14.00 | Aug 19, 2026 |
| FORMELA JEAN FRANCOISInsider | Sell | $68K | 4,884at $14.00 | Aug 19, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable KRRO activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.